BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression ...
– Data provide insights that informed the Phase 1 study of STK-002 as a potential disease-modifying medicine for ADOA, including disease etiology, progression and clinical assessments – – ADOA is a ...
Autosomal dominant optic atrophy (ADOA), the most common genetic optic neuropathy, is an insidious disease. It often presents slowly during childhood by way of blurry vision, trouble reading or ...
Autosomal dominant optic atrophy (ADOA), the most common genetic optic neuropathy, is an insidious disease. It often presents slowly during childhood by way of blurry vision, trouble reading or ...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression ...
Stoke Therapeutics (NASDAQ:STOK) presented its second quarter 2025 business update on August 12, highlighting progress across its pipeline of RNA-based therapies for severe genetic diseases. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback